The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.
A draft summary went online briefly on the WHO Web site and was first reported by the Financial Times and health news Web site Stat, which posted a screenshot.
However, Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying that the data showed a “potential benefit.”
Photo: AFP
The Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group, the summary said, adding that remdesivir was stopped early in 18 patients because of side effects.
The authors said that remdesivir was “not associated with a difference in time to clinical improvement” compared with the control.
After a month, 13.9 percent of the patients on remdesivir had died, compared with 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
“We believe the post included inappropriate characterizations of the study,” a Gilead spokesman told reporters, adding that it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman said.
The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
Last week, Stat reported that it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.
The US National Institutes of Health also reported it that had proven effective in a small experiment on monkeys.
Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA, and gets absorbed into the virus’ genome, which in turn stops the pathogen from replicating.
Anti-malarial drugs hydroxychloroquine and chloroquine have also been widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.
Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically engineered mice that were deliberately infected.
Separately in France, new research shows that nicotine could protect people from contracting COVID-19.
The findings came after researchers at a top Paris hospital examined 343 COVID-19 patients, as well as 139 people with the illness who had milder symptoms.
They found that a low number of them smoked, compared with smoking rates of about 35 percent in France’s general population.
“Among these patients, only 5 percent were smokers,” said Zahir Amoura, the study’s coauthor and a professor of internal medicine.
The research echoed similar findings published in the New England Journal of Medicine last month suggesting that 12.6 percent of 1,000 people infected in China were smokers.
That was a much lower figure than the number of regular smokers in China’s general population, about 26 percent, WHO data showed.
The theory is that nicotine could adhere to cell receptors, therefore blocking the novel coronavirus from entering cells and spreading in the body, said neurobiologist Jean-Pierre Changeux from France’s Pasteur Institute, who also coauthored the study.
The researchers are awaiting approval from health authorities to carry out further clinical trials.
The researchers are looking into whether nicotine could help to prevent “cytokine storms,” a rapid overreaction of the immune system that scientists think could play a key role in fatal COVID-19 cases.
However, with further research needed, experts are not encouraging people to pick up smoking or use nicotine patches as a protective measure against the virus.
“We must not forget the harmful effects of nicotine,” French Director-General for Health Jerome Salomon said.
“Those who do not smoke should absolutely not use nicotine substitutes,” which cause side effects and addiction, he said.
Crowds in Bangladesh are flocking to snap photographs with an unlikely social media star — an albino buffalo with flowing blond hair nicknamed “Donald Trump” that is due to be sacrificed within days. Owner Zia Uddin Mridha, 38, said his brother named the 700kg bull over its flowing helmet of hair resembling the signature look of the US president. “My younger brother picked this name because of the buffalo’s extraordinary hair,” he said at his farm in Narayanganj, just outside the capital, Dhaka. Mridha said that a constant stream of curious visitors — social media fans, onlookers and children — have come throughout
It began as a satirical online project. Now millions of young people in India are flocking to it as an outlet for their frustration. A parody political party called the Cockroach Janta Party, with the insect as its symbol, has exploded across India’s social media by turning absurdist humor into protest. Memes and short videos mocking corruption, joblessness and political dysfunction have flooded social media sites, where millions of users are embracing the cockroach — known for its ability to survive harsh conditions — as a tongue-in-cheek symbol of endurance. The online movement’s rise has been unusually rapid. The Cockroach Janta Party (CJP)
HOTTER: While Indians are accustomed to summer heat, climate change has caused northwestern India to warm faster than other parts of the country, an academic said Roads and markets have emptied during afternoons and some farmers have switched to nighttime work to avoid scorching temperatures as a heat wave grips large parts of India. The India Meteorological Department forecast maximum temperatures for yesterday of about 45°C in the capital, New Delhi, where authorities have opened temporary “cooling zones” to help people cope. The weather department warned that conditions would likely persist across several northern regions in the coming days, with temperatures staying well above seasonal averages. Authorities urged people to stay indoors during the hottest hours and take precautions against heat-related illnesses. India declares a heat wave whenever maximum temperatures
A Hong Kong astronaut is to join a Chinese space mission for the first time as part of a three-person crew launching today, as Beijing edges closer to its goal of landing people on the moon. The Tiangong space station — crewed by teams of three astronauts that are typically rotated every six months — is the crown jewel of China’s space program, boosted by billions in state investment in a bid to catch up with the US and Russia. The Shenzhou-23 mission is to blast off at 11:08pm from the Jiuquan Satellite Launch Center in northwestern China, carrying three astronauts to
RSS